These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34105910)

  • 21. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J; Babusíková O
    Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative differences in CD8+ lymphocytes, CD4/CD8 ratio, NK cells, and HLA-DR(+)-activated T cells of racially different male populations.
    Shahabuddin S
    Clin Immunol Immunopathol; 1995 May; 75(2):168-70. PubMed ID: 7704975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
    de Weerdt I; Hofland T; de Boer R; Dobber JA; Dubois J; van Nieuwenhuize D; Mobasher M; de Boer F; Hoogendoorn M; Velders GA; van der Klift M; Remmerswaal EBM; Bemelman FJ; Niemann CU; Kersting S; Levin MD; Eldering E; Tonino SH; Kater AP
    Blood Adv; 2019 Sep; 3(17):2642-2652. PubMed ID: 31506282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [An analysis of immunophenotyping of peripheral lymphocytes in adult patients with infectious mononucleosis and chronic active Epstein-Barr virus infection].
    Xie J; Wang HL; Qiu ZF; Li TS
    Zhonghua Nei Ke Za Zhi; 2016 Jun; 55(6):455-9. PubMed ID: 27256608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
    Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
    Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
    Podhorecka M; Goracy A; Szymczyk A; Kowal M; Ibanez B; Jankowska-Lecka O; Macheta A; Nowaczynska A; Drab-Urbanek E; Chocholska S; Jawniak D; Hus M
    Oncotarget; 2017 May; 8(21):34661-34669. PubMed ID: 28416773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4, CD8 and NK subsets in B-CLL.
    Vuillier F; Tortevoye P; Binet JL; Dighiero G
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):331-4. PubMed ID: 3265505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
    Manna A; Kellett T; Aulakh S; Lewis-Tuffin LJ; Dutta N; Knutson K; Chini E; Pinilla-Ibarz J; Lamanna N; Manochakian R; Malavasi F; Sher T; Chanan-Khan AA; Ailawadhi S; Paulus A
    Blood Adv; 2020 May; 4(10):2143-2157. PubMed ID: 32421811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland.
    Bisset LR; Lung TL; Kaelin M; Ludwig E; Dubs RW
    Eur J Haematol; 2004 Mar; 72(3):203-12. PubMed ID: 14962239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
    Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
    Front Immunol; 2021; 12():619069. PubMed ID: 34108958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis.
    Martinez A; Pittaluga S; Villamor N; Colomer D; Rozman M; Raffeld M; Montserrat E; Campo E; Jaffe ES
    Am J Surg Pathol; 2004 Jul; 28(7):849-58. PubMed ID: 15223953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.
    Costa-García M; Ataya M; Moraru M; Vilches C; López-Botet M; Muntasell A
    Front Immunol; 2019; 10():687. PubMed ID: 31001281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).
    Porakishvili N; Roschupkina T; Kalber T; Jewell AP; Patterson K; Yong K; Lydyard PM
    Clin Exp Immunol; 2001 Oct; 126(1):29-36. PubMed ID: 11678896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
    Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
    Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of immunophenotype, lymphocytic subsets and NK cells in patients with B cell chronic lymphoid leukemia].
    Zhang L; Zhu L; Wang HW; Yang LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):36-9. PubMed ID: 19236743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of dietary ribonucleotides on infant immune status. Part 2: Immune cell development.
    Buck RH; Thomas DL; Winship TR; Cordle CT; Kuchan MJ; Baggs GE; Schaller JP; Wheeler JG
    Pediatr Res; 2004 Dec; 56(6):891-900. PubMed ID: 15496603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.